trial · primary record
Selenomethionine (SLM)
Clear Cell Renal Cell Carcinoma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 15 |
| Primary completion | 2026-08-25 |
| Primary endpoint | Phase I - Dose limiting toxicities using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0 |
| Registry ID | NCT05363631 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:47:25.454Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05363631
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.